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ARTICLE
The circadian clock components BMAL1 and REV-
ERBα regulate ﬂavivirus replication
Xiaodong Zhuang1, Andrea Magri1, Michelle Hill2, Alvina G. Lai1, Abhinav Kumar2, Srinivasa Bhargav Rambhatla3,
Claire L. Donald 4, Andrea F. Lopez-Clavijo5, Simon Rudge5, Katherine Pinnick6, Wai Hoong Chang1,
Peter A. C. Wing1, Ryan Brown7, Ximing Qin 8, Peter Simmonds1, Thomas F. Baumert9, David Ray 10,
Andrew Loudon10, Peter Balfe 3, Michael Wakelam5, Sam Butterworth11, Alain Kohl4, Catherine L. Jopling12,
Nicole Zitzmann 2 & Jane A. McKeating1
The circadian clock regulates immune responses to microbes and affects pathogen replica-
tion, but the underlying molecular mechanisms are not well understood. Here we demon-
strate that the circadian components BMAL1 and REV-ERBα inﬂuence several steps in the
hepatitis C virus (HCV) life cycle, including particle entry into hepatocytes and RNA genome
replication. Genetic knock out of Bmal1 and over-expression or activation of REV-ERB with
synthetic agonists inhibits the replication of HCV and the related ﬂaviruses dengue and Zika
via perturbation of lipid signaling pathways. This study highlights a role for the circadian clock
component REV-ERBα in regulating ﬂavivirus replication.
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The cell-autonomous circadian clock coordinates the net-work of physiological processes that deﬁne the dailyrhythms of cell proliferation, metabolism and inﬂamma-
tion1. Clock signalling pathways are primarily controlled by the
transcription activators BMAL1 and CLOCK. The nuclear hor-
mone receptors REV-ERBα and REV-ERBβ are BMAL1-
regulated clock components that provide a feedback loop that
controls the expression of metabolic genes in a circadian and
tissue-dependent manner2. Host innate and adaptive immune
response are now recognised to be circadian regulated and to
inﬂuence susceptibility to infectious agents and response to vac-
cines3–6. Pariollaud et al. recently reported a homeostatic role for
REV-ERBα in regulating pulmonary inﬂammation, coupling the
core clock to innate immunity7.
As obligate intracellular parasites viruses require host cell
machineries and metabolites to replicate their viral genome and
to assemble progeny virions. Recent studies reporting increased
replication of herpes, inﬂuenza8, respiratory syncytial virus and
parainﬂuenza type 39 in Bmal1 knock-out mice suggest a role for
circadian pathways to deﬁne host susceptibility to virus infection,
however, the molecular mechanisms are not well understood. The
recent availability of synthetic REV-ERB ligands that modulate
circadian pathways in vivo10,11 provide tools to study the role of
REV-ERB in viral replication and open exciting therapeutic
opportunities for treating infectious disease.
The Flaviviridae family of positive-strand RNA viruses are
major causes of morbidity and mortality and include the human
pathogens: hepatitis C (HCV), dengue (DENV) and Zika (ZIKV)
viruses. DENV infects around 390 million people per year12 and
the recently emerged ZIKV has been estimated to infect 750,000
individuals annually since 201513. To date, no anti-viral treat-
ments are available for either virus. In contrast, the recent
development of direct acting anti-viral agents (DAAs) against
HCV infection has revolutionised treatment options14. However,
given the high cost and limited availability of these drugs, sig-
niﬁcant numbers of chronic HCV-infected individuals remain at
risk to develop progressive liver disease and hepatocellular car-
cinoma15. Despite differences in their transmission and patho-
genesis, all of these viruses replicate in the cytoplasm and subvert
lipid homeostatic pathways to induce organelle-like membrane
structures that support viral replication16.
The liver maintains an organism’s metabolic homeostasis and
REV-ERBα plays a key role in regulating bile acid and fatty acid
biosynthesis17–19. As HCV replicates solely in hepatocytes within
the liver and there are excellent in vitro model systems available
to study its replication, we investigated the role of circadian clock
components in the HCV life cycle. We show a circadian cycling of
HCV entry into hepatocytes that is deﬁned via BMAL1 regulation
of entry receptors CD81 and claudin-1. Furthermore, we show
that REV-ERB overexpression or activation with synthetic ago-
nists inhibits HCV, DENV and ZIKV RNA replication, high-
lighting a new role for REV-ERB to restrict RNA virus
replication.
Results
HCV infection is circadian regulated. The human hepatocyte-
derived cell line Huh-7 provides a well-characterised in vitro
model to study the HCV life cycle and virus–hepatocyte inter-
actions. Several approaches have been reported to synchronise the
circadian clock in cell culture and we compared protocols that
used dexamethasone, serum shock or temperature ﬂuctuation to
synchronise Huh-7 cells. Serum shocking the cells was the opti-
mal protocol to coordinate the cycling of Bmal1 and Rev-Erbα
mRNA transcripts for 48 h (Fig. 1a), with the amplitude
decreasing thereafter. Viral entry into a host cell represents the
ﬁrst step in the infectious life cycle and is mediated via speciﬁc
interactions between virus proteins and cellular receptors that
deﬁne particle internalisation pathways. Lentiviruses can incor-
porate exogenous viral encoded glycoproteins and the resulting
pseudoparticles (pp) undergo a single cycle of infection that
enable the study of receptor-speciﬁc internalisation pathways20.
Synchronised Huh-7 cells at different circadian times (CTs) were
inoculated with HCVpp for 1 h, unbound virus was removed by
washing and infection was measured after 24 h (Fig. 1b). HCVpp
entry was maximal at CT8 and CT32 (Fig. 1c). Delivering the
lentiviral DNA directly into cells showed that serum-induced
circadian synchronisation had no effect on reporter activity per se
suggesting an HCV glycoprotein receptor-dependent pathway
(Supplementary Figure 1A). Infecting synchronised cells at CT0
or CT8 with pseudotyped viruses expressing HCV or vesicular
stomatitis virus (VSV) glycoproteins conﬁrmed that CT8 cells
support greater levels of HCVpp infection that was not apparent
for VSVpp infection (Supplementary Figure 1B). The infectious
HCV cell culture (HCVcc) system recapitulates the complete viral
life cycle and we evaluated the infectivity of two well-
characterised HCVcc strains, J6/JFH-1 and SA13/JFH-1, to
infect Huh-7 cells at deﬁned CTs. Infection was quantiﬁed by
counting viral antigen NS5A expressing cells and we observed a
signiﬁcant increase in infected cell numbers when the virus was
inoculated at CT8 (Fig. 1d), suggesting that circadian pathways
regulate HCV uptake into the liver.
HCV entry into hepatocytes is regulated by four essential host
factors: CD81, scavenger receptor BI (SR-BI), claudin-1 and
occludin21. We investigated whether any of the viral receptors
showed circadian expression and demonstrated a rhythmic
pattern of CD81, claudin-1 and occludin mRNA levels in
synchronised Huh-7 cells (Fig. 1e), with the peak of viral receptor
transcripts coinciding with peak Bmal1 mRNA levels and particle
uptake. To establish a link between BMAL1 and receptor
expression, we transiently silenced Bmal1 in Huh-7 cells and
observed a signiﬁcant reduction in CD81 and claudin-1
transcripts (Supplementary Figure 2). CRISPR knockout (KO)
of Bmal1 in Huh-7 cells conﬁrmed a signiﬁcant reduction in
CD81 and claudin-1 mRNA and protein levels, with no detectable
change in occludin (Fig. 1f). Importantly, these Bmal1 KO cells
were resistant to HCVpp and HCVcc infection compared with
wild-type (WT) cells (Fig. 1g). To ascertain whether BMAL1
regulates DENV or ZIKV infection, we infected the KO Huh-7
cells and observed a signiﬁcant reduction in the replication of
both viruses in Bmal1 KO cells compared with WT (Fig. 1h). As
the mechanism of particle entry for these viruses into hepatocytes
is poorly deﬁned and the tools to study viral uptake are not well
developed, we selected to study the role of BMAL1 in HCV entry.
In summary, these data support a role for BMAL1 to regulate
HCV, DENV and ZIKV infection.
Pharmacological activation of REV-ERB inhibits HCV entry.
Bmal1 is negatively regulated at the transcriptional level by REV-
ERBs, haem-binding transcriptional repressors22. The develop-
ment of synthetic agonists that activate REV-ERB and modulate
circadian pathways in vivo10,11 prompted us to investigate their
ability to regulate HCV infection. REV-ERB agonists, SR9009 and
GSK2667, reduced BMAL1 promoter activity in a dose-
dependent manner (Supplementary Figure 3) and we conﬁrmed
a reduction in endogenous mRNA levels and protein expression
(Figs. 2a, b) with no detectable cytotoxicity or effect on hepato-
cellular viability (Supplementary Figure 3). To exclude the pos-
sibility of global transcriptional repression by these agonists, we
assessed the expression level of nine housekeeping genes in
treated Huh-7 cells and found no signiﬁcant changes in their
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mRNA levels (Supplementary Figure 4). REV-ERB agonists
treated Huh-7 cells showed a signiﬁcant reduction in CD81
expression assessed by western blotting with negligible effects on
claudin-1 or occludin expression (Fig. 2b). As measuring protein
expression by western blotting is semiquantitative and partly
deﬁned by afﬁnity and avidity of the antibodies being used, we
selected a non-biased proteomic approach to assess the effect of
SR9009 on viral receptor expression. We observed a signiﬁcant
reduction in CD81 and claudin-1 expression with an increase in
occludin levels and no signiﬁcant change in SR-BI (Fig. 2c).
Importantly, both REV-ERB agonists inhibited HCVpp entry in a
dose-dependent manner (Fig. 2d). To evaluate the activity of
these agonists against a wider spectrum of HCV strains, we
utilised lentiviral pseudotypes expressing genetically diverse
envelope glycoproteins and demonstrated inhibition of all strains
tested (Fig. 2e). In summary, these data highlight a role for REV-
ERB to regulate CD81 and claudin-1 protein expression and
deﬁne circadian gating of HCV entry.
REV-ERB limits HCV RNA replication. HCV can establish a
persistent infection and sub-genomic copies of the viral RNA can
replicate autonomously. These replicon systems have been widely
used as pre-clinical models for anti-viral drug discovery. Short
hairpin RNA silencing Rev-erbα in Huh-7 cells stably supporting
HCV-luciferase replicon increased viral replication (Figs. 3a, b),
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demonstrating a role for REV-ERB to regulate viral genome
replication after particle entry. Furthermore, treating HCV
replicon cells with REV-ERB agonist SR9009 reduced viral
replication in a dose-dependent manner and efﬁcacy was sig-
niﬁcantly reduced in the shRev-erbα cells compared with control
cells (Fig. 3b), conﬁrming the anti-viral activity of SR9009 is
dependent on REV-ERB protein levels. We noted that the
endogenous expression of REV-ERBα in Huh-7 cells was low
(Fig. 3a) and hypothesised that overexpression would limit HCV
replication. Transient expression of REV-ERBα in HCV replicon
cells inhibited viral genome replication in a dose-dependent
manner (Fig. 3c). Given these promising data, we assessed the
effect of REV-ERB agonists to modulate genome replication in
HCVcc-infected cells, where a neutralising anti-CD81 receptor
antibody was included to block secondary infection events23. We
observed a dose-dependent reduction in HCV RNA levels and
NS5A-expressing cells with both agonists (Fig. 3d). Transient
delivery of HCV RNA into Bmal1 KO cells bypassed the
restriction in viral receptor-dependent particle entry and enabled
us to show that REV-ERB agonist SR9009 inhibits HCV repli-
cation in WT and Bmal1 KO cells (Supplementary Figure 5),
showing a role for REV-ERB to regulate HCV RNA replication
independent of Bmal1 expression. Finally, we demonstrate that
both REV-ERB agonists inhibit the replication of diverse HCV
genotypes 1b (Con1), 2a (JFH-1) and 3a (S52)24 (Fig. 3e).
REV-ERB regulates miR-122. HCV RNA binds the liver-speciﬁc
microRNA miR-122 and this complex has been reported to
support the replication of the viral RNA25. As REV-ERBα reg-
ulates miR-122 and both primary (pri)-miR-122 transcription
and miR-122 target genes show circadian patterns of expres-
sion26, we were interested to investigate the miR-122 dependency
of REV-ERB restriction of HCV replication. Synchronised Huh-7
cells show a circadian pattern of pri-miR-122 expression (Fig. 4a)
and REV-ERB agonists reduced pri-miR-122 levels (Fig. 4b). Co-
transfection of a miR-122 antagonist along with HCV RNA into
Huh-7 cells reduced virus replication as previously reported25 and
both REV-ERB agonists showed reduced anti-viral activity (Fig.
4c), suggesting a role for REV-ERB regulation of miR-122 in
restricting HCV replication. To investigate further, we evaluated
the sensitivity of a HCV variant encoding a mutated miR-122
binding motif that recognised miR-15a/b27 (m15) to REV-ERB
agonists. Both SR9009 and GSK2667 inhibited m15 replication
with comparable efﬁciency as WT virus (Fig. 4d), demonstrating
that REV-ERB agonists inhibit HCV replication independent of
miR-122 binding to the viral RNA. As miR-122 regulates
cholesterol and lipid metabolism28, this most likely contributes to
the anti-viral activity of REV-ERB agonists to limit HCV
replication.
REV-ERBα regulates pathways essential for HCV, DENV and
ZIKV. REV-ERBα regulates lipid and cholesterol metabolism in
the murine liver19,29. As lipids play a role in the genesis and
maintenance of membranous vesicles that are essential for RNA
virus replication and particle assembly16, we investigated the effect
of the REV-ERB agonists on de novo lipogenic pathways in human
hepatocytes. As SR9009 showed the highest anti-viral activity and
has been extensively studied in vivo, we performed a whole-
genome microarray on SR9009 (20 µM) treated Huh-7 cells.
Differentially expressed genes from the microarray data were
ﬁltered through the following criteria: Log2 fold change
magnitude > 0.5, a p-value < 0.05, which generated a list compris-
ing 4033 upregulated genes and 3660 downregulated genes (most
highly regulated genes are listed in Supplementary Data 1).
KEGG pathway analysis of the differentially expressed genes
identiﬁed an enrichment of metabolic pathways involved in
lipogenesis and cholesterol/bile acid metabolism (Figs. 5a, b). We
demonstrated that SR9009 reduced stearoyl-CoA-desaturase
(SCD) promoter activity, mRNA transcript levels and protein
expression assessed by western blotting and proteomics analysis
(Fig. 5c). Furthermore, SR9009-treated Huh-7 cells showed a
signiﬁcant reduction in unsaturated fatty acid levels (16:1/
16:0—ctrl 0.42v SR9009 0.38, p = 0.0018; 16:1+ 18:1n-7—ctrl
20.41v SR9009 18.98, p = 0.0001; 16:1+ 18:1n-7/16:0—ctrl 0.77v
SR9009 0.72, p = 0.0065), a phenotype consistent with reduced
SCD expression and activity. Trump et al. reported that REV-ERB
agonists activate the nuclear receptor LXRα in human monocyte
THP1 cells10. As LXR regulates metabolic pathways that overlap
with REV-ERBα, we evaluated the ability of SR9009 to activate
LXR and demonstrated a negligible effect on known LXR target
gene transcription in human hepatocytes (Supplementary Fig-
ure 6). Analysis of published ChIP-seq data30 on REV-ERB
chromatin occupancy in murine liver showed evidence of binding
the SCD1 promoter (Fig. 5d). Overexpressing REV-ERBα in
Huh-7 cells reduced SCD expression in a dose-dependent manner
(Fig. 5e), consistent with our earlier data showing that
endogenous REV-ERBα levels are low in Huh-7 cells (Fig. 3c).
Cumulatively, these data show for the ﬁrst time a role for REV-
ERBα to regulate SCD in human hepatocytes.
As SCD is rate limiting for HCV infection31,32, we investigated
the contribution of this pathway to REV-ERB regulation of HCV
replication. Oleic acid is the ﬁnal product of SCD and can restore
de novo lipogenesis pathways in cells lacking SCD.
Fig. 1 HCV entry is circadian regulated. a Synchronisation of Huh-7 cells. Huh-7 cells were serum shocked and Bmal1 and Rev-Erbα mRNA measured by
quantitative reverse transcription polymerase chain reaction (qRT-PCR) and expressed relative to circadian time (CT) 0. Data are the average of four
independent experiments (n= 4). b Circadian infection protocol. Synchronised Huh-7 were inoculated with HCVpp or HCVcc particles for 1 h and
infectivity determined by luciferase assay or measuring the frequency of viral NS5A expressing cells 24 h later. c HCV entry shows a circadian pattern.
Synchronised Huh-7 cells were inoculated with HCVpp at deﬁned CTs and particle entry measured 24 h later and data expressed relative to CT0; mean ± S.
E.M., n= 8, Kruskal–Wallis ANOVA with Dunn’s test. d HCV infection shows a circadian pattern. Synchronised Huh-7 were inoculated with HCVcc SA13/
JFH-1 or J6/JFH-1 at deﬁned CTs and the frequency of infected cells quantiﬁed 24 h later and data expressed relative to CT0; mean ± S.E.M., n= 4;
Kruskal–Wallis ANOVA with Dunn’s test. e Circadian pattern of HCV receptors. Synchronised Huh-7 were lysed every 8 h, total RNA extracted and CD81,
claudin-1 and occludin mRNA levels together with the housekeeping GAPDH assessed by qPCR. Individual receptor transcripts were normalised to CT0.
Representative of three independent experiments; n= 3, mean ± S.E.M. f BMAL1 regulates HCV entry receptors. Parental (WT) or Bmal1 KO Huh-7 lysates
were assessed for BMAL1 and viral receptors CD81, claudin-1 and occludin expression together with housekeeping GAPDH by western blotting. Total RNA
from parental or Bmal1 KO Huh-7 were extracted and mRNA of CD81, claudin-1, occludin and GAPDH measured by qRT-PCR. Data are expressed relative to
parental cells (mean ± S.E.M., n= 3, Mann–Whitney test). g BMAL1 regulates HCV entry and infection. WT or Bmal1 KO Huh-7 were inoculated for 1 h with
HCVpp or HCVcc SA13/JFH-1 and infection assessed after 24 h. Data are expressed relative to WT cells (mean ± S.E.M., n= 5, Mann–Whitney test).
h BMAL1 regulates DENV and ZIKV infection. WT or Bmal1 KO Huh-7 were inoculated for 1 h with DENV or ZIKV and infection assessed after 24 h. Data
are expressed relative to WT (mean ± S.E.M., n= 6 for DENV; n= 9 for ZIKV, Mann–Whitney test)
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Supplementing the culture media with oleic acid had a negligible
effect on HCV replication (Supplementary Figure 7) but reduced
the anti-viral activity of SR9009 and control SCD inhibitor (Fig.
5f). Furthermore, CRISPR knock-down (KD) of SCD in HCV
replicon cells inhibits viral replication and reduced the anti-viral
activity of SR9009 and SCDi (Fig. 5g), demonstrating that REV-
ERB perturbation of SCD expression contributes to its anti-viral
activity.
As the replication of many ﬂaviviruses is dependent on fatty
acid biosynthesis33, we investigated a role for REV-ERB in
the replication of DENV and ZIKV. Transient expression of
REV-ERBα in Huh-7 cells using a dose of plasmid previously
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shown to inhibit HCV replication signiﬁcantly reduced DENV
and ZIKV replication (Fig. 6a). Treating Huh-7 cells with REV-
ERB agonist SR9009 reduced DENV or ZIKV infection, as
assessed by measuring secreted levels of viral RNA and infectious
particles (Fig. 6b). Furthermore, CRISPR KD of SCD in DENV or
ZIKV-infected Huh-7 cells reduced viral replication and the anti-
viral activity of SR9009 (Fig. 6c), highlighting SCD as a common
pathway for REV-ERB to regulate this family of viruses.
Discussion
In this study, we examined the interplay between the circadian
regulatory pathways and the replicative life cycle of HCV, DENV
and ZIKV. Our results provide the ﬁrst mechanistic evidence for
circadian gating of HCV entry into hepatocytes via the regulation
of entry receptors CD81 and claudin-1, providing a potential
mechanism for our earlier observation reporting a time-of-day
dependence in HCV re-infection kinetics following liver
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transplantation34. We discovered a new role for REV-ERB to
regulate HCV, DENV and ZIKV RNA replication by repressing
SCD expression (Fig. 7). Given the wide number of target genes
that REV-ERB can regulate, we cannot exclude the possibility of
additional pathways contributing to its anti-viral activity.
However, our data provide the ﬁrst evidence that pharmacolo-
gical modulation of circadian pathways can inhibit viral replica-
tion. Targeting host pathways that are essential to virus
replication can provide therapies that generate limited resistance
and such chronotherapies may work synergistically with DAAs.
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Our data showing rhythmic expression of CD81, claudin-1 and
occludin transcripts in Huh-7 cells along with reduced CD81 and
claudin-1 protein expression and HCVpp entry into Bmal1 KO
cells, support an interplay between BMAL1 and REV-ERB to
regulate HCV entry into hepatocytes. Analysis of published ChIP-
seq datasets35,36 from murine liver failed to identify BMAL1
binding to CD81 or claudin-1 promoter regions. However,
claudin-1 and occludin mRNAs show a rhythmic expression in
murine liver37 and claudin-1 was reported to be among the top
upregulated genes in Rev-erba KO mice18. Du et al. reported that
CD81 transcription was rhythmic in murine liver in phase con-
sistent with REV-ERB target, but this did not result in rhythmic
mRNA accumulation possibly due to high stability of the tran-
script38. Recent reports demonstrating a role for CD81 in the
assembly and budding of human immunodeﬁciency virus and
inﬂuenza A viruses39,40 highlight the wider implications of our
observation that CD81 is circadian regulated for other human
pathogens.
Our observation that inhibiting miR-122 reduced the anti-viral
activity of REV-ERB agonists for HCV suggests that circadian
regulation of HCV replication is in part miR-122 dependent. Of
note, Esau and colleagues reported that miR-122 regulates cho-
lesterol and lipid metabolism where silencing miR-122 in mice
reduced the mRNA levels of key genes that regulate lipid meta-
bolism, including SCD and fatty acid synthase (FASN)28. Our
observation that a REV-ERB agonists inhibits HCV replication
independent of miR-122 binding to the viral RNA, suggests an
indirect modulation of HCV replication via perturbing lipid
metabolism.
Recent studies reporting increased replication of herpes,
inﬂuenza, respiratory syncytial virus and parainﬂuenza type 3
viruses in Bmal1-/- mice suggest that BMAL1 negatively regulates
viral infection8,9. However, these studies did not address the
underlying mechanism. Our observation that HCV, DENV and
ZIKV show reduced replication in Bmal1 KO hepatocytes high-
lights the diverse roles of BMAL1 in the life cycle of different
virus families that requires further investigation. In vivo small
animal models for studying HCV, DENV or ZIKV replication
frequently use immunocompromised mice41–43 that limit studies
to evaluate the immunomodulatory role of BMAL1 or REV-ERB
in the viral life cycle.
Since virus infection, replication and particle assembly are
dependent on cellular membranes, we examined the lipid com-
position of SR9009-treated Huh-7 cells and observed changes in
both neutral (particularly triglycerides) and phospholipids.
Notably, the lipidomic analysis highlighted selective changes in
lipid molecular species, rather than a generalised change sug-
gesting selective effects on lipid turnover. Of particular note was
the 60% reduction in total cellular phosphatidic acid concentra-
tion, reﬂected almost exclusively in the mono- and di-unsaturated
species (Supplementary Figure 8). This reduction is an expected
consequence of SCD downregulation reducing monounsaturated
fatty acid generation and is likely to induce a profound effect on
cellular membranes. Phosphatidic acid is unique in that its small,
highly charged head group is close to its glycerol backbone,
allowing it to induce a high membrane curvature, which may play
a role in viral RNA replication and particle assembly. In contrast,
the unsaturated phosphatidic acids are more loosely packed in the
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Fig. 6 REV-ERB inhibits DENV and ZIKV replication. a Overexpressing REV-ERBα inhibits DENV and ZIKV replication. Huh-7 cells harbouring sub-genomic
DENV RNA or ZIKV-Nanoluc were transfected with REV-ERBα expression plasmid or Ctrl empty vector (2 µg). DENV or ZIKV replication was assessed by
measuring luciferase activity 48 h later and data expressed relative to untreated Ctrl cells (mean ± S.E.M., n= 4, Mann–Whitney statistical test). REV-ERB
expression was conﬁrmed by western blotting. b REV-ERB agonist SR9009 inhibits DENV and ZIKV infection. Huh-7 cells were infected with DENV2 16681
at a MOI of 0.1 and treated with SR9009 for 48 h (n= 3). Extracellular viral RNA and the infectious titre of secreted virus was quantiﬁed and the data
expressed relative to untreated Ctrl cells, where the mean titre of virus secreted from untreated cells was 1.6 × 105 pfu/ml. Huh-7 cells were infected with
ZIKV MP1751 at an MOI of 0.1 and treated with SR9009 for 48 h. Extracellular RNA and infectious titre was quantiﬁed and the data expressed relative to
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and ZIKV replication. DENV replicon cells or ZIKV-Nanoluc infected cells were transfected with CRISPRs targeting exons 2 and 3 of SCD or a scrambled
guide RNA and 24 h later treated with SR9009. SCD expression was measured by western blotting and the dose of REV-ERB agonist required to inhibit
DENV or ZIKV replication by 50% (IC50) in WT or KD cells determined (mean ± S.E.M., n= 6, Mann–Whitney statistical test)
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membrane and induce less curvature. Consequently, we propose
that the selective loss of mono- and di-unsaturated phosphatidic
acid species will have a major effect on membrane structure and
intracellular viral function.
Ultrastructural and functional studies show a role for SCD in
the genesis of viral replication compartments or ‘replication fac-
tories’ in HCV, DENV and ZIKV44 but also West Nile33, human
immunodeﬁciency virus45, respiratory syncytial virus and other
respiratory viruses46, extending the signiﬁcance of our observa-
tions to a wider spectrum of human pathogens. These viral
replication factories serve multiple purposes: (1) spatial separa-
tion of different steps in the viral replication cycle, namely, RNA
translation, replication and packaging of viral genomes into
particles to prevent interference; (2) enabling a high local con-
centration of viral replicase complex components and metabolites
such as nucleotides to maximise RNA ampliﬁcation and (3)
protecting newly synthesised viral RNA from innate immune
surveillance. To date, our understanding of the role circadian
factors play in viral replication at a cellular level is limited. Our
ﬁndings show new pathways for the circadian network to impact
multiple stages of the HCV, DENV and ZIKV replication cycles.
As the transcriptional clock mechanism is universal and exists in
all cells of the body, our study has implications for the circadian
regulation of many viruses that rely on host metabolic activities to
replicate33,45–47.
Methods
Cell culture. The human hepatoma cell line Huh-7 (gift from C. Rice, Rockefeller
University, NY) and HCV sub-genomic replicon line A2-Luc48 (gift from R.
Thimme, University of Freiburg, Germany) were maintained in Dulbecco’s
modiﬁed Eagle’s medium (DMEM)/10% foetal bovine serum (FBS)/1% non-
essential amino acids/1% penicillin/streptomycin (Invitrogen, Carlsbad, CA). Huh-
7 cells were synchronised by treating with culture medium containing 50% FBS for
1 h. Bmal1 KO Huh-7 clones were generated by transfecting a pool of three BMAL1
CRISPR/Cas9 KO plasmids (Santa Cruz Biotechnology, UK) followed by ﬂuores-
cence activated cell sorting (FACs) and clonal expansion. LLC-MK2 and AFRIMS
kidney cells (ATCC, UK) were maintained in M199 medium/10% FBS/1% peni-
cillin/streptomycin. Vero epithelial kidney cells (ATCC, UK) were maintained in
DMEM/10% FBS/1% penicillin/streptomycin.
Reagents and antibodies. Following reagents were purchased from commercial
suppliers: REV-ERBα expression plasmid (Origene, UK); SCD promoter-luc
plasmid (Genecopoeia, UK); REV-ERB agonist SR9009 (Calbiochem, US); Dacla-
tasvir and Sofosbuvir (Selleckchem, US) and SCD inhibitor A939572 (BioVision,
US). REV-ERB agonist GSK2667 was synthesised at University of Birmingham10.
All drugs were dissolved in dimethyl sulfoxide (DMSO) and their cytotoxicity
determined by a Lactate dehydrogenase (LDH) assay (Promega, UK). The fol-
lowing primary antibodies were used: anti-NS5A 9E10 (1 µg/mL, C. Rice, Rock-
efeller University), anti-CD81 (1 µg/mL, 2.131)49, anti-claudin-1 (1 µg/mL,
Abcam, UK), anti-occludin (2 µg/mL, Invitrogen, UK), anti-BMAL1 (1 µg/mL,
Abcam, UK), anti-REV-ERBα (1 µg/mL, Thermo Fisher Scientiﬁc, UK); anti-SCD
(1 µg/mL, Abcam, UK) and anti-GAPDH (1 µg/mL, Cell Signaling, US). Uncrop-
ped original western blots are shown in Supplementary Figure 9. Fluorescent Alexa
Fluor 488-conjugated anti-mouse secondary antibodies were obtained from Invi-
trogen, UK.
The BMAL1 promoter was ampliﬁed from genomic DNA using forward
primer: 5ʹ-CCGCTCGAGGGGACAACGGCGAGCTCGCAG-3ʹ and reverse
primer: 5ʹ-CCCAAGCTTCGGCGGCGGCGGCGGCAAGTC-3ʹ and cloned into
the pGL3 luciferase reporter vector (Promega, UK). Lenti-shRev-Erbα construct
was a gift from Dr. B. Grimaldi, University of Genoa, Italy. To generate SCD KD
cells, CRISPR guide RNA (gRNA) forward and reverse sequences were designed
using CRISPR Finder (https://www.sanger.ac.uk/htgt/wge/ﬁnd_crisprs) with
overhang sequences containing a BbsI restriction site50. The gRNA sequences were
annealed and cloned into BbsI-digested pSpCas9(BB)-2A-Puro (PX459) V2.0 DNA
(Addgene plasmid #62988; deposited by Dr. Feng Zhang). The CRISPR gRNA
plasmid products were sequenced to conﬁrm successful cloning. SCD exon 2 gRNA
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Fig. 7 Model of circadian clock components regulating HCV, DENV and ZIKV replication. The circadian activator BMAL1 regulates HCV entry into
hepatocytes through modulating viral receptors CD81 and claudin-1 expression. Activating REV-ERB with synthetic agonists or protein overexpression
inhibits HCV, DENV or ZIKV RNA replication via modulating SCD and subsequent release of infectious particles
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sequences: exon 2 forward—5ʹ-CACCGGCCTTCCTTATCCTTGTAGG-3ʹ and
exon 2 reverse 5ʹ-AAACCCTACAAGGATAAGGAAGGCC-3ʹ. SCD exon 3 gRNA
sequences: exon 3 forward—5ʹ-CACCGGCAGCCGAGCTTTGTAAGAG-3ʹ and
exon 3 reverse- 5ʹ-AAACCTCTTACAAAGCTCGGCTGCC-3ʹ. All primers used
are detailed in Supplementary Table 1.
HCVcc/HCVpp genesis and infection. Plasmids encoding HCV SA13/JFH and
J6/JFH were transcribed to generate viral RNA that was electroporated into Huh-7
cells51. Infected cells were ﬁxed with ice-cold methanol, stained for viral antigen
expression with anti-NS5A (9E10) and an isotype-matched Alexa-488 conjugated
IgG. Viral antigen-expressing cells were enumerated using a ﬂuorescent micro-
scope. HCV RNA levels were assessed by quantitative reverse transcription poly-
merase chain reaction (qRT-PCR). Luciferase reporter pp expressing HCV
envelope glycoproteins (HCVpp), or no-glycoprotein controls, were generated in
293T cells20 using a plasmid encoding a HIV provirus expressing luciferase and
viral envelope glycoproteins from HCV lab strains H77 and from patient-derived
clones52. Circadian synchronised or 24 h drug-treated Huh-7 cells were inoculated
with pp for 1 h, lysed 24 h later and luciferase activity measured.
DENV and ZIKV infection. DENV2 strain 16681 was grown in 6/36 cells, con-
centrated by precipitation with 10% weight per unit volume (w/v) poly(ethyle-
neglycol) (PEG) MW 8000 (Sigma, UK)/0.6% sodium chloride. Huh-7.5 cells were
seeded into 24-well plates and 24 h later infected with DENV2 16681 at a multi-
plicity of infection (MOI) of 1 for 90 min at room temperature (RT). Unbound
virus was removed by washing and cultures treated with SR9009 or control DMSO
and incubated for 48 h. Supernatants were harvested and the infectious titre
determined by plaque assay on LLC-MK2 cells. Viral RNA was extracted from the
supernatant using the Qiagen Viral RNA mini kit according to the manufacturer’s
protocol.
ZIKV strain MP1751 (PHE, UK) was propagated in Vero cells, concentrated by
precipitation with 8% w/v PEG in NTE buffer. Huh-7.5 cells were infected with
ZIKV strain MP1751 at an MOI of 0.1 for 90 min at RT, unbound virus was
removed by washing and the cultures treated with SR9009 or control DMSO and
incubated for 48 h. Supernatants were harvested and the infectious titre determined
by plaque assay on Vero cells. Viral RNA was extracted from the supernatant using
the Qiagen Viral RNA mini kit according to the manufacturer’s protocol.
The pCCl-SP6- ZIKV-Nanoluc plasmid53 was used as a template to generate
genomic DNA by PCR using the following primers: forward 5ʹ-CGATTAAGTT
GGGTAACGCCAGGGT-3ʹ and reverse 5ʹ-TAGACCCATGGATTTCCCCA
CACC-3ʹ. The DNA was transfected into Vero E6 cells (ATCC, CCL-81) using
Lipofectamine 2000 as per the manufacturer’s instructions (Thermo Fisher
Scientiﬁc). Virus stocks were titrated in the A549/BVDV-Npro cell line54. Huh-7.5
cells were infected with ZIKV-Nanoluc at an MOI of 0.1 and treated with SR9009 or
DMSO vehicle alone for 48 h and Nluc activity measured using the Nano-Glo kit
(Promega).
Real-time reverse transcription PCR. Puriﬁed total RNA samples were tested for
HCV RNA expression (Primer Design Ltd, UK) in a qRT-PCR as per the manu-
facturer’s guidelines (CellsDirect Kit; Invitrogen, UK) in an MxPro-3000 PCR
machine (Aligent, US). Comparison of a panel of 12 housekeeping genes (GeNorm
kit, Primer Design Ltd. UK) identiﬁed GAPDH as a stably expressed reference
gene. Primer sets for BMAL1, REV-ERBα, CD81, claudin-1, occludin and common
housekeeping genes were purchased from Thermo Fisher Scientiﬁc, UK. For SCD a
primer set consisting of forward: 5ʹ-CTCTGCTACACTTGGGAGCC-3ʹ and
reverse: 5ʹ-GAGCTCCTGCTGTTATGCCC-3ʹ was used in a SYBR green qRT-PCR
(Qiagen, UK).
DENV and ZIKV RNA was assayed by qRT-PCR on an Applied Biosystems
7500 real-time PCR system using the Verso 1-step RT-PCR kit with Thermo-start
Taq (Applied Biosystems) as per the manufacturer’s guidelines. The primer and
probe sequences were adapted from previously published methods55,56. For DENV,
the NS5 primer set consisted of forward 5ʹ-ACAAGTCGAACAACCTGGTCC-3ʹ,
reverse 5ʹ-GCCGCACCATTGGTCTTCTC-3ʹ and probe 5ʹ-(6FAM) CCAGTGG
AATCATGGGAGGAAATCCCA(TAM)-3ʹ. For ZIKV, the envelope primer set
consisted of forward 5ʹ-TCGTTGCCCAACACAAG-3ʹ, reverse 5ʹ-CCACTAATGT
TCTTTTGCAGACAT-3ʹ and probe 5ʹ-(6FAM) AGCCTACCTTGACAAGCAAT
CAGACACTCAA(TAM)-3ʹ. Secreted DV RNA was quantiﬁed using a standard
curve generated from high titre viral RNA isolated from C6/36 grown DENV2.
Secreted ZIKV RNA was quantiﬁed using a standard curve generated from an RNA
oligonucleotide comprising the 77 bases of ZIKV RNA targeted by the assay
primers.
HCV and DENV sub-genomic replicons. Plasmids encoding the HCV and DENV
sub-genomic replicons were generated57,58. The HCV L-GDD con1 (genotype 1b),
JFH-1-luc (genotype 2a) and S52-ΔN (genotype 3a) were linearised with XbaI
(New England Biolabs, UK), treated with Mung Bean nuclease (NEB, UK) and the
linearised templates used to transcribe RNAs24. Plasmid pDVRepPAC-LUC
encodes a ﬁreﬂy luciferase (LUC) gene in place of DENV2 C, prM and E genes and
a NS2B-NS3 cleavage site at the C-terminus enables cleavage from the rest of the
polyprotein. In all, 2 μg of HCV or DENV RNA was electroporated into 4 × 106
cells and allowed to recover for 48 h before treating with REV-ERB ligands. Huh-7
cells stably expressing HCV RNA were generated from N17 plasmid59. Cells were
seeded in 96-well plates, incubated with Vivo-Glo (Promega, UK) and monitored
in real-time at 30-min intervals over a 24-h period on a microplate reader (Clar-
iostar, BMG Labtech, UK).
Microarray and ChIP-seq analyses. Microarray datasets for SR9009 treated Huh-
7 cells (20 µM, 24 h treatment, n= 3) were obtained from Oxford Gene Tech-
nology, UK. Differentially expressed genes were ﬁltered using the following para-
meters: p-value < 0.05, log2FC > 0.5 or log2FC < –0.5. KEGG proﬁling60 was used to
perform pathway mapping and determine signiﬁcantly enriched pathways using
hypergeometric tests. Metabolic-related pathways were extracted and represented
as bar charts with the colour of each bar indicative of its p-value. ChIP-seq datasets
for murine REV-ERBα and REV-ERBβ were obtained from Gene Expression
Omnibus where peak detection was performed using the HOMER tool. BedGraphs
are visualised using the Integrative Genomics Viewer (IGV) tool61 overlaying the
mouse genome (mm10).
Analysis of cellular triacylglycerol fatty acids and phospholipids. Total lipids
from mock or SR9009 (20 µM)-treated Huh-7 cells were extracted using the Folch
method62. The triacylglycerol fraction was separated using solid phase extraction
columns and fatty acid methyl esters (FAMEs) prepared by incubating with
methanolic sulphuric acid at 80 °C for 2 h63. Gas chromatography was performed
using an Agilent 6890N GC (Agilent Technologies, Stockport, UK)64 and indivi-
dual fatty acid peaks identiﬁed by reference to known FAMEs and fatty acid peak
areas converted to mol (%). Phospholipids were analysed by mass spectrometry65
and lipids resuspended in chloroform/methanol (1:1) prior to injection into a
Shimadzu Prominence 20 AD system (Shimadzu, Kyoto, Japan). Chromatographic
separation was achieved upon a Cogent HPLC column (150 × 2.1 mm, 4 µm par-
ticle size) column kept a 40 °C. Mobile phase A: isopropanol/hexane/100 mM
ammonium formate (58:40:2), mobile phase B: isopropanol/hexane/100 mM
ammonium formate with 0.5% of formic acid (50:40:10). The gradient started at
10% B (5 min), with an increase to 90% B for 5 min, 100% B was reached after an
additional 10 min and held for 7 min before re-equilibrating with 10% B for 5 min.
The ﬂow rate was maintained constant at 200 µL/min. Accurate mass (with an
error below 5 ppm) was acquired on an Orbitrap Elite mass spectrometer (Thermo
Fisher Scientiﬁc, USA). Source parameters for negative polarity were: capillary
temperature 325 °C; source heater temperature 325 °C; sheath gas 10 AU; aux gas 5
AU; sweep gas 5 AU. Source voltage was 3.2 kV. Full scan spectra in the range of
m/z 200–1000 were acquired at a target resolution of 240,000 (FWHM at m/z 400).
Data were analysed using Lipid Data Analyzer (2.6.0–2) software.
Proteomic analysis. Three biological replicates of control and SR9009-treated
Huh-7 cells were lysed in RIPA buffer and proteins separated using NuPAGE
4–12% bis-tris gels (Invitrogen). Peptides obtained from selected proteins (CD81,
claudin-1, occludin, SR-BI, occluding, SCD) using in-gel trypsin digestion (tryptic
digestion kit, Thermo) were detected and quantiﬁed using Liquid chromatography
tandem mass spectrometry (LC-MS/MS) methods. Peptides were desalted using an
online C18 trap column (PepMap 100, 5 µm particle size, 300 µm i.d. × 5 mm,
Thermo Fisher Scientiﬁc) at a ﬂow rate of 10 µL/min for 4 min. The nano LC
system Dionex Ultimate 3000 (RSLC nano system) and a nano analytical C18
reversed phase column (PepMap), dimensions 75 µm × 50 cm, 2 µm particle size
(Thermo Fisher Scientiﬁc) were used, with a ﬂow rate of 250 nL/min at 45 oC ( ± 2
oC). The mobile phase was solvent A: 0.1% v/v formic acid in water, and solvent B:
0.1% v/v formic acid in acetonitrile/water (80:20 v/v). A four step-gradient (0–4.5
min: 2% B, 4.5–105 min: 25% B, 105–125 min: 40% B and 125–131 min: 95% B)
was used to separate peptides on the nano analytical column. Mass spectrometry
was performed using a bench top Q Exactive hybrid quadrupole-Orbitrap mass
spectrometer (Thermo Scientiﬁc) for data-dependent acquisition (DDA) and
parallel reaction monitoring (PRM). DDA was used for detection and library
creation of peptides for the purpose of PRM-based quantitation. DDA method
settings: Chromatographic peak width: 12 s, the full MS conditions used—resolu-
tion: 70,000, AGC target: 3e6, maximum injection time (IT): 60 ms, scan range:
375–1500 m/z. The dd-MS2 conditions—resolution: 17,500. The AGC target con-
ditions—1e5, maximum IT: 60 ms, loop count: 10 (i.e., Top 10), isolation width:
2.0 m/z, ﬁxed ﬁrst mass: 100.0 m/z, and the data-dependent (dd) settings—mini-
mum AGC target: 2e3, intensity threshold: 3e4, charge exclusion: unassigned, 1, > 8,
peptide match; preferred, dynamic exclusion: 20 s. Normalised collision energy
(NCE) of 27 was used for fragmentation of peptides in a high-energy collision
dissociation (HCD) cell. PRM method settings: global settings—user role:
advanced; lock mass: best; chromatographic peak width: 20 s; full MS-SIM setting
—resolution: 17,500; AGC target: 5e;4 maximum IT: 20 ms; t-MS2 settings—
polarity: positive; in-source collision induced dissociation (CID): 0.0 eV; default
charge: 2; inclusion: on; microscan: 1; resolution: 70,000; AGC target: 2e;5 max-
imum IT: 200 ms; MSX count: 1; isolation window: 1.6 m/z; normalised collision
energy (NCE): 27; spectrum type: proﬁle. The MS tune ﬁle for nano ﬂow rate at
250 nL/min was used with the following settings: scan type: full MS-SIM, scan
range: 350–2000 m/z, fragmentation: none, resolution: 70,000, polarity: positive,
microscan: 1, AGC target: 1e6, maximum IT: 100, sheath gas ﬂow: 0, aux gas ﬂow:
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0, sweep gas ﬂow: 0, spray voltage: 2.3 kV, capillary temperature: 320 oC, S-lens RF
level: 50. Data acquired using DDA were processed using the Mascot search engine
against human Uniprot protein database. Mascot search results were uploaded to
Skyline (version 4.1.0.18169, 64-bit, Seattle, USA) to create a reference library.
PRM data were processed using Skyline to quantify peptides in different samples.
Statistical analysis. Statistical analyses were performed in Graph Pad Prism 7
(GraphPad, USA) using Mann–Whitney’s test or Kruskal–Wallis one-way analysis
of variance (ANOVA) with Dunn’s test (for multiple comparisons), except where
stated otherwise, with a p-value of < 0.05 considered statistically signiﬁcant (*p ≤
0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001).
Reporting summary. Further information on experimental design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The metabolomics data have been deposited to the EMBL-EBI MetaboLights
database (DOI: 10.1093/nar/gks1004. PubMed PMID: 23109552) with the identiﬁer
MTBLS792. The mass spectrometry proteomics data have been deposited to the
ProteomeXchange Consortium via the PRIDE [1] partner repository with the
dataset identiﬁer PXD011721 and 10.6019/PXD011721, and can be accessed via:
ftp://PASS01292:YF2765va@ftp.peptideatlas.org/. The microarray data from
SR9009 treated Huh-7 cells have been deposited at NCBI GEO with the identiﬁer
GSE123748 and can be accessed via http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE123748. The authors declare that all other data supporting the
ﬁndings of this study are available within the article and its Supplementary
Information ﬁles, or are available from the authors upon request.
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